bl-b01d1,patritumab,blu-945,telisotuzumab
blueprint medicines,amgen,abbvie,biokin pharma,daiichi sankyo
['bl-b01d1', 'teliso', 'patritumab', 'blu 945 ']
 many better options in post egfr progression than torturing pts with io based regimens -
bl-b01d1 bispecific , ami or teliso depending on met expression , patritumab in all comers and myriad of adcs , blu 945 esp for c 797s .. .. 
Hem-Onc - Doing my part to help onc patients. + fintwit